Conditions: Acute Leukemia
Keywords: leukemia induction prophylaxis antifungal micafungin phase II
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 66
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether prophylaxis with micafungin is effective in the induction chemotherapy for newly diagnosed acute leukemia patients.

Detailed description:
Medically fit patients with newly diagnosed acute leukemia received 50 mg micafungin intravenously once daily from the initiation of first induction chemotherapy to recovery of neutrophil count, suspected fungal infection, or unacceptable drug-related toxicity.

Arms:
arm 1: Patients received 50 mg micafungin intravenously once daily from the initiation of induction chemotherapy to recovery of neutrophil count (absolute neutrophil count \> 500/μg for three consecutive days), suspected fungal infection, or occurrence of drug-related toxicity.

Interventions: intervention 1: Micafungin
Intervention descriptions: intervention 1: None

Protocol document:
Prot_SAP_ICF_000.pdf: 
Micafungin prophylaxis for acute leukemia patients undergoing induction chemotherapy 
 
 
Trial Registration: Clinicaltrials.gov NCT02440178, registered May 12, 2015  
Document Date: October 10, 2021 
 
 
Methods 
Study Design 
In this prospective, single-arm, open-label study (Clinicaltrials.gov number, NCT02440178), 
we enrolled patients with newly diagnosed acute leukemia (AML, acute lymphoblastic 
leukemia [ALL], and acute biphenotypic leukemia [ABL]) who received intensive induction 
chemotherapy at Seoul National University Hospital (SNUH) and Seoul National University 
Bundang Hospital from September 2015 through June 2017. All patients enrolled in the study 
provided written informed consent. Inclusion criteria were as follows: 1)  18 years old; 2) 
Acute leukemia diagnosed by bone marrow examination; 3) intensive induction chemotherapy; 
4) Eastern Cooperative Oncology Group performance status score ≤ 2; and 5) serum creatinine 
and bilirubin levels < 1.5 times the upper limit of the reference range for our laboratory. 
Exclusion criteria were as follows: 1) suspected fungal infection 30 days before initiation of 
induction chemotherapy; 2) history of hypersensitivity to echinocandin; 3) diagnosis of other 
malignancy in the previous 5 years; 4) previous chemotherapy, radiation, or 
immunosuppressive treatment; 5) immunodeficiency disease; 6) pregnant or breastfeeding; 7) 
uncontrolled seizures or mental illness; 8) acute myocardial infarction, uncontrolled arrhythmia, 
or low ejection fractions (< 40%); 9) previous organ transplantation; and 10) interstitial lung 
disease.  
Patients received 50 mg micafungin intravenously once daily from the initiation of 


induction chemotherapy to recovery of neutrophil count (absolute neutrophil count > 500/μg 
for three consecutive days), suspected fungal infection, or occurrence of drug-related toxicity. 
The primary end point was incidence of invasive fungal infection, and the secondary end points 
were adverse events of prophylactic micafungin and mortality during induction chemotherapy. 
Patients were followed up for 6 and 12 weeks after the initiation of induction chemotherapy 
for the occurrence of fungal infection and survival, respectively. 
 
The determination of sample size 
The previous study showed that the incidence of fungal infections was about 29.2% in 
prophylactic fluconazole group and 13.8% in posaconazole group. We hypothesized that the 
incidence of fungal infections in the prophylactic micafungin group was reduced by 15.4% 
(assuming that the incidence is similar to that of the prophylactic posaconazole group) from 
that of prophylactic fluconazole group. Therefore, a sample size of 65 patients was required for 
this study based on a statistical power of 80% and a significance level of 5%, including a 
dropout rate of 10%.  
 
Diagnosis of invasive fungal infection 
For all patients, baseline chest x-rays were obtained within 7 days after the initiation of 
induction chemotherapy. Aspergillus infection was diagnosed according to the criteria for 
invasive pulmonary aspergillosis of the European Organization for Research and Treatment of 
Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and 
Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. An invasive 
fungal infection was defined as “proven” by a positive culture for fungus with symptoms and 
signs of a fungal infection, as “probable” by direct or indirect detection (galactomannan 
antigen or serum β–D-glucan) with clinical and radiographic findings, or as “possible” if 


sufficient clinical evidence for fungal infection was present without mycological evidence.  
 
 
Statistical Analysis 
Categorical variables were compared using Pearson’s chi-square test or Fisher’s exact test, as 
appropriate. Cumulative incidence of fungal infection and the time from initiation of 
micafungin treatment to a switch to another antifungal agent were evaluated by Kaplan–Meier 
analysis. All analyses were performed using SPSS for Windows, version 23.0 (IBM; Armonk, 
NY, USA); All statistical tests were two-sided, and significance was defined as P < 0.05. 
 
Ethical Considerations 
This study was approved by the institutional review board at Seoul National University 
Hospital (IRB; H-1412-022-631) and was conducted in accordance with the guidelines of the 
Declaration of Helsinki for biomedical research. Informed consent was obtained from all 
participants. 
 
 
 
 
 
 
 
 
 
 
 
 


Informed consent 
 
The information is prepared to explain the contents of this research. If you have any 
questions, please ask the principal investigator or other investigator.  
 
1. Clinical Trial Title 
Micafungin Prophylaxis During 1st Induction Chemotherapy for De Novo Acute Leukemia 
 
2. Principal Investigator 
Professor Youngil Koh, Department of Hematology and Oncology 
 
3. Background 
In acute leukemia, neutropenia persists for a long time during inducing chemotherapy, which 
leads to the occurrence of invasive fungal infection. The need for prophylactic antifungal agents 
has been continuously demanded, and micafungin is currently used as a prophylactic antifungal 
agent in pretreatment for hematopoietic stem cell transplantation. Although micafungin is 
currently used for the treatment of fungal infections, it has not been established as a preventive 
agent in induction therapy for acute leukemia. 
 
4. Investigational drugs 
Micafungin 
- Efficacy/Effect: 
1) Treatment of esophageal candidiasis 
2) Prevention of fungal infection in hematopoietic stem cell transplant recipients 
 
5. Precautions for use: 
1) Warning 
Severe hypersensitivity has been reported. If hypersensitivity occurs, administration of this 
drug should be stopped immediately and appropriate treatment will be needed. 
2) Other clinically significant adverse events are as follows. 
① Vascular and lymphatic disorders: coagulation disorders, hemolysis, hemolytic anemia, 
pancytopenia, thrombotic thrombocytopenic purpura 
② Cardiac abnormalities: arrhythmias, cardiac arrest, cyanosis, myocardial infarction, 
tachycardia 
③ Hepatobiliary disorders: hepatocellular damage, hepatomegaly, jaundice, liver failure 


④ General adverse reactions and administration site abnormalities: thrombus at the 
administration site 
⑤ Infection and invasion of pathogens: infection, pneumonia, sepsis 
⑥ Metabolic and nutritional abnormalities: acidosis, anorexia, hyponatremia 
⑦ Musculoskeletal, connective tissue, bone abnormalities, joint pain 
⑧ Nervous system abnormalities: convulsions, brain disease, intracranial hemorrhage 
⑨ Kidney and urinary disorders: anuria, hemoglobinuria, oliguria, acute renal failure, renal 
tubular necrosis 
⑩ Respiratory, chest and septal abnormalities: apnea, dyspnea, hypoxia, pulmonary embolism 
⑪ Skin and subcutaneous tissue abnormalities: erythema multiforme, skin necrosis 
 
6. Clinical trial period 
Subjects will receive this drug from the day they start induction therapy to the day they recover 
from neutropenia. The research team will evaluate the incidence of fungal infection up to 6 
weeks and survival up to 12 weeks after initiation of induction therapy. 
 
7. Clinical trial method 
If you participate in this study, you will receive a free supply of micafungin. Patients received 
50 mg micafungin intravenously once daily from the initiation of induction chemotherapy to 
recovery of neutrophil count (absolute neutrophil count > 500/μg for three consecutive days), 
suspected fungal infection, or occurrence of drug-related toxicity. Chest imaging and fungal 
serology will be performed once a week. If necessary, culture tests for body fluids such as 
sputum and blood may be performed. The drug is discontinued when the neutrophil count 
exceeds 500 or exceeds 3000 for 3 days or more. In addition, a blood test to evaluate fungal 
infection at the 6th week is needed. 
 
8. Benefits for study subjects 
By reducing the frequency of fungal infections, you can benefit from hospital stay and cost of 
treatment. 
 
9. Expenses and Compensation 
Participation in this clinical trial may provide you with a free supply of antifungal drugs, but 
may not have any other benefit. For the evaluation of fungal infection, chest imaging tests, 
blood tests, and culture tests for body fluids are needed. These tests are performed depending 


on the patient's condition. 
 
10. Requirements for study subjects  
There are no special requirements for study subjects. If you are discharged from the hospital 
after treatment, you must visit the hospital for evaluation of fungal infection at the 6th and 12th 
weeks from the date of induction chemotherapy.  
 
11. Voluntary participation/discontinuation of study 
Participation in clinical trials is entirely up to you. If you do not agree to participate in the 
clinical trial, it does not matter at all. In addition, even after consenting to participate in the 
trial, you can withdraw your consent to participate in the clinical trial at any time if you wish, 
and there will be no disadvantage or damage. 
 
12. Continuous provision of new research-related information 
If the investigator becomes aware of any new facts during the study, the investigator will inform 
you or your representative of the facts at any time. 
 
13. Damage and compensation 
Although this drug is currently marketed and used, unexpected side effects may occur. 
Compensation will be determined in accordance with regulations related to Seoul National 
University Hospital and separate compensation agreements with insurance companies. Damage 
compensation can be compensated up to a maximum of 500 million per accident and 100 
million per person. 
 
14. Confidentiality 
All records of your identity obtained in this research will be kept confidential, and even when 
the results are published, your personally identifiable information will be kept confidential.  
 
15. Contact person 
If additional information is needed regarding the clinical trial and the rights and interests of the 
subject, or in case of damage related to the clinical trial, contact: 02-743-7617 (research nurse), 
other emergency contact information, if you have any questions about the research, etc.) IRB 
(Institutional Review Board, Medical Research Ethics Review Board): 02-2072-0694 
Clinical Research Ethics Center Contact: 02-2072-3509